Report On Experiences with Excipient Audits
The industry initiative EXCiPACT was launched a year ago to improve monitoring of pharmaceutical excipients. At the CPHI China in Shanghai and the ExcipientFest Europe in Amsterdam, the auditors of blue inspection body have now drawn an initial conclusion: “Overall, the level of awareness for good manufacturing and good distribution practices at excipient manufacturers has increased significantly in the past 12 months,” declared lead auditor Dr Norbert Waldöfner in a presentation at the IPEC China Excipient Regulatory and Quality Control Seminar during the CPHI in Shanghai. “This is certainly partly due to the fact that the regulatory authorities have placed a stronger focus on the topic.” Shortly before, one of blue’s shareholders, Dr Stefan Kettelhoit had already informed the participants at the ExcipientFest congress Europe in Amsterdam about the experiences with the first EXCiPACT audits.
One difficulty with audits of excipients such as lactose, cellulose or glycerol is that GMP and GDP standards do not apply to all parts of the company being audited, explained Dr Norbert Waldöfner: “In many cases, only a small part of production is destined for the pharmaceutical industry.” In such cases, documentation of the respective batches is particularly important.
EXCiPACT initiative aims for certified monitoring of excipients
The EXCiPACT initiative was established by industrial associations of excipient suppliers and the pharmaceuticals industry. The aim is to merge and standardise surveillance audits of Good Manufacturing and Good Distribution Practice of pharmaceutical excipients. “The slogan is ‘Less but more professional audits’, meaning that EXCiPACT has defined particularly high standards for every single audit”, explained Dr Stefan Kettelhoit from blue inspection body GmbH: “This ensures that third-party audits of excipient manufacturers are also internationally recognised by regulatory bodies.” In the past, pharmaceutical companies conducted their own audits, which meant that excipient manufacturers were sometimes confronted with over 100 audit requests from different customers.
CPHI China and ExcipientFest Europe
CPHI China is part of CPHI Worldwide. With around 30,000 visitors from 102 countries, the trade fair in Shanghai is one of the largest events for contract manufacturers and exporters of pharmaceutical products worldwide. The ExcipientFest congress is specifically aimed at producers and users of excipients for the production of medicinal products. It is staged alternately at venues in the United States, Europe and Asia.
The blue inspection body GmbH examines the Good Manufacturing Practices (GMP) of pharmaceutical companies around the globe. Third-party audits by blue efficiently relieve manufacturing authorisation holders, API suppliers and API manufacturers. Blue inspection body GmbH is the first independent and accredited service provider for GMP audits in the European Union.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance